Zoetis receives FDA approval for beef implant products
Three reimplant combinations now available for feedyard producers.
August 3, 2022
Zoetis has received expanded label approval from the Food and Drug Administration's Center for Veterinary Medicine on three beef implant products. Synovex Choice is the foundation of new reimplant labels that are now available to feedlot operations, which also include Synovex Plus and Synovex One Feedlot.
"This approval provides beef producers with enhanced flexibility to more broadly use these technologies to help them meet their production and profitability goals," says John Hallberg, DVM, PhD, U.S. director of regulatory affairs, Zoetis. "The performance benefits of Synovex Choice, Synovex Plus and Synovex One Feedlot have long been proven and this is the logical next step for the industry."
These three products are approved for reimplanting programs in both steers and heifers fed in confinement for slaughter. The three reimplantation labels include:
Synovex Choice followed by Synovex Choice, 60 to 120 days later
Synovex Choice followed by Synovex Plus, 60 to 120 days later
Synovex Choice followed by Synovex One Feedlot, 60 to 120 days later
Effective immediately, existing packages of Synovex Choice, Synovex Plus and Synovex One Feedlot can be used in reimplanting programs at feedlots. Animal health product suppliers and cattle producers will begin seeing updated labels with the approved reimplantation language by the end of 2022.
"The Synovex brand has contributed more than 66 years of growth productivity and innovation to the U.S. beef cattle industry," says Paul Parker, senior marketing manager, Zoetis. "We recognized the need and committed our resources to seek approval for these reimplant labels. These new label indications provide cattle feeders with proven options to help optimize performance in a profitable and sustainable manner."
Source: Zoetis, which is solely responsible for the information provided, and wholly owns the information. Informa Business Media and all its subsidiaries are not responsible for any of the content contained in this information asset.
You May Also Like